高风险MDS和CMML的低甲基化剂加上venetoclax作为移植的桥梁疗法:GESMD研究

Ines Zugasti1,2,3, Monica Lopez-Guerra1,4,5, Sandra Castaño-Díez1,2,4

  • 1Hospital Clínic Barcelona, Barcelona, Spain.

概括

低甲基化剂和venetoclax (HMA/VEN) 组合表明,它有望为患有高风险骨髓分裂性综合征 (HR-MDS) 和慢性骨髓单细胞白血病 (CMML) 的患者架起桥梁,以实现全源干细胞移植 (allo-SCT). 这种方法实现了高响应率,并在大多数患者中促进了alo-SCT.

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
260
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K